Zhiyong Liu

Prof. Dr. Zhiyong Liu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in IEEE Transactions on Instrumentation and Measurement
Verified
Journal Article
Closed access
SXShenghao Xue
Shenghao Xue
Yaochun HouYaochun Hou
Yaochun Hou
JJJianxiang Jin
Jianxiang Jin
ZLZhiyong Liu
Zhiyong Liu
WHWeiting He
Weiting He
WHWenjun Huang
Wenjun Huang
Centrifugal compressors (CCs) are critical equipment for compressing and transporting various gases in chemical production. As a type of vane compressor, their stable and reliable operation can be compromised by issues such as surge, rotating stall, and other malfunctions. Traditional diagnostic approaches for CCs typically depend on a singular signal, such as vibration analysis, which can be one-sided and overlook substantial amounts of information. Additionally, multi-source-signal fusion diagnostic methods for CCs are relatively scarce. With this in mind, a mechanism-data fusion diagnostic approach for CC aerodynamic failure based upon Bayesian extreme learning machine (BELM) is proposed in this article. Firstly, the vibratory data is processed using wavelet packet decomposition (WPD) and various statistical features are extracted from different scales. The Relief-F algorithm is then employed to select the most significant feature set, which are subsequently leveraged to train the BELM data-driven model. Next, mechanism-knowledge-based indices of process parameter signals (e.g., pressure, flow) are designed and calculated, and a mechanism-based diagnostic model can be derived via utilizing the fuzzy inference system (FIS). In the implementation stage, the sparse representation of FIS results is conducted at first, followed by the diagnostic information fusion attained through the optimization of BELM parameters. Finally, experimental validations on CC datasets as well as comparison analyses with other information fusion methods sufficiently certify the effectiveness and superiority of the developed approach.

8 March 2026 in Cancer Medicine
Verified
Journal Article
Open access
ZLZhiyong Liu
Zhiyong Liu
RCRan Chen
Ran Chen
Background: To investigate the role and mechanism of SLC12A8 in the progression of Luminal B breast cancer. Methods: Data from TCGA, GTEx, and HPA databases were used to analyze SLC12A8 expression and its prognostic value in breast cancer. qPCR was performed to validate SLC12A8 expression in various breast cancer cell lines. The correlation between SLC12A8 and immune cell infiltration was analyzed using ImmuCellAI and TIMER databases. Gene set enrichment analysis (GSEA) was employed to predict signaling pathways associated with SLC12A8. In vitro, siRNA‐mediated knockdown of SLC12A8 or treatment with the TLR pathway inhibitor GIT27 was used to assess the effects on the TLR pathway, CD8 + T cell function (as indicated by PD‐1, PRF1, and GZMB expression), and cancer cell invasion via Western blot, immunofluorescence, qPCR, and Transwell assays. CD8 + T cells were isolated from healthy human peripheral blood using magnetic bead separation (Miltenyi Biotec, CD8 MicroBeads) and activated with anti‐CD3/CD28 beads prior to co‐culture. Additional functional assays included IFN‐γ/IL‐2 ELISA and cytotoxicity assays. Results: SLC12A8 was significantly upregulated in breast cancer tissues and cell lines, and its high expression correlated with poor patient prognosis. Bioinformatic analysis and experimental validation confirmed that high SLC12A8 expression was strongly associated with reduced infiltration and functional inhibition of CD8 + T cells in the tumor microenvironment, particularly in Luminal B breast cancer. Mechanistically, SLC12A8 activated the TLR signaling pathway (upregulating TLR2, MyD88, IRAK1, TAK1 in CD8 + T cells), leading to increased PD‐1 expression on CD8 + T cells, resulting in their functional exhaustion and enhanced invasive ability of Luminal B breast cancer cells. Knockdown of SLC12A8 or TLR pathway inhibition reversed these effects. Overexpression of SLC12A8 in normal breast epithelial cells recapitulated the exhausted T‐cell phenotype, and TLR2 agonist treatment mimicked SLC12A8 effects. Conclusion: SLC12A8 promotes immune evasion and metastasis in Luminal B breast cancer by inducing CD8 + T‐cell exhaustion via activation of the TLR signaling pathway, suggesting its potential as a prognostic biomarker and therapeutic target.

1 June 2025 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
ZLZhiyong Liu
Zhiyong Liu
XMXiaoshan Meng
Xiaoshan Meng
RCRan Chen
Ran Chen
Introduction: This study compared the efficacy, complications, and related indicators of High-Intensity Focused Ultrasound Ablation (HIFU) and Radiofrequency Ablation (RFA) for treating benign breast tumors, aiming to provide effective evidence-based support for clinical practice. Methods: This study is a retrospective study. A retrospective analysis was conducted on data from patients undergoing thermal ablation surgery at The First Affiliated Hospital of Gannan Medical University between February 2021 and May 2024, divided into the HIFU group (147 cases, 231 tumors) and the RFA group (151 cases, 193 tumors), with perioperative indicators, postoperative efficacy, effective ablation rate, complications, prognosis, and satisfaction statistically analyzed. Results: The groups showed no significant differences in age, BMI, tumor diameter/volume, or proportion of tumors across size categories, ensuring comparability. Operative time was shorter for HIFU than RFA (p < 0.005), though hospital stay was longer for HIFU (p < 0.05). Intra/postoperative pain was lower in the HIFU group (p < 0.05). At 6 months post-op, volume reduction was greater with HIFU (p < 0.05); specifically, for tumors ≤1 cm no significant difference existed (p > 0.05), but for tumors >1–2 cm and >2–3 cm, HIFU showed superior volume reduction (p < 0.05). Overall volume change favored HIFU (p < 0.05). The effective ablation rate at 6 months was significantly higher for HIFU (p < 0.05), including for multiple lesions (p < 0.05). Postoperative pain scores (NRS) were significantly lower with HIFU (p < 0.05), and treatment satisfaction rates were significantly higher in the HIFU group (p < 0.05). Conclusion: Both HIFU and RFA are safe and effective for benign breast tumors.

25 May 2026 in Cancer Informatics
Verified
Journal Article
Open access
HHHong Hu
Hong Hu
CZChao Zhang
Chao Zhang
ZLZhiyong Liu
Zhiyong Liu
Objectives: To investigate the mechanism by which Hesperidin (Hsp) inhibits the proliferation and metastasis of the triple-negative breast cancer cell line MDA-MB-231. Methods: The effect of Hsp on cell viability was analyzed using the MTT assay. The anti-migration and anti-invasion abilities of Hesperidin were evaluated using the scratch test and Transwell migration assay. The activity of matrix metalloproteinases (MMP)-2/MMP-9 was analyzed using gelatin zymography. The expression of epithelial-mesenchymal transition (EMT)-related proteins (Vimentin, Snail, ZO-1) was detected by Western blot. Results: Low concentrations of Hsp (2–10 μmol/L) showed no significant cytotoxicity; 20–40 μmol/L significantly reduced cell survival rate (p<0.01). The scratch test showed that Hsp inhibited wound healing in a concentration-dependent manner. The Transwell migration assay showed that the number of migrating cells decreased with increasing Hsp concentration. Gelatin zymography results indicated that MMP-2/MMP-9 activity decreased with increasing Hsp concentration. Western blotting results showed that Hsp downregulated the metastasis-related proteins Vimentin and Snail and upregulated the adhesion protein ZO-1. Conclusion: Our findings suggest that Hsp inhibits tumor cell invasion and metastasis by potentially reducing MMP-2/MMP-9 hydrolase activity, blocking extracellular matrix degradation, and reversing the EMT process (downregulating Vimentin/Snail and upregulating ZO-1). Hsp may represent a promising candidate for adjuvant therapy in breast cancer.

1 January 2026 in International Journal of Clinical and Experimental Pathology
Verified
Journal Article
Closed access
ZLZhiyong Liu
Zhiyong Liu
Objective: To investigate the mechanism of Hesperidin (Hsp) in inhibiting the proliferation and metastasis of breast cancer cell line MDA-MB-231. Methods: The effect of Hsp on cell survival rate was analyzed using the MTT assay. The anti-migration and anti-invasion abilities of Hesperidin were evaluated using the scratch test and Transwell migration assay. The activity of matrix metalloproteinases (MMP)-2/MMP-9 was analyzed using gelatin zymography. The expression of epithelial-mesenchymal transition (EMT)-related proteins (Vimentin, Snail, ZO-1) was detected by Western blot. Results: Low concentrations of Hsp (2-10 μmol/L) showed no significant cytotoxicity; 20-40 μmol/L significantly reduced survival rate (P<0.01). Scratch test results showed that Hsp inhibited wound healing in a concentration-dependent manner. Transwell migration assay showed that the number of migrating cells decreased with increasing Hsp concentration. Gelatin zymography results indicated that MMP-2/MMP-9 activity decreased with increasing Hsp concentration; Western Blotting results showed that Hsp downregulated the metastasis-related proteins Vimentin and Snail and upregulated the adhesion protein ZO-1. Conclusion: Our findings suggest that Hsp inhibits tumor cell invasion and metastasis by potentially reducing MMP-2/MMP-9 hydrolase activity, blocking extracellular matrix degradation, and reversing the EMT process (downregulating Vimentin/Snail and upregulating ZO-1). Hsp may represent a promising candidate for adjuvant therapy in breast cancer.

1 March 2026 in AME Case Reports
Verified
Journal Article
Open access
PDF file
ZLZhiyong Liu
Zhiyong Liu
RCRan Chen
Ran Chen
Background: Contralateral axillary lymph node metastasis (CAM) following radical mastectomy for breast cancer is a rare and clinically challenging event, with a reported incidence of approximately 1.9% to 6.0%. Its pathogenesis, often attributed to altered lymphatic drainage after primary breast surgery, is not fully elucidated. The classification of CAM remains controversial, as current American Joint Committee on Cancer (AJCC) staging guidelines categorize it as distant metastasis (M1), while emerging clinical evidence suggests its biological behavior and prognosis may align more closely with advanced regional (stage III) disease. This ambiguity complicates management, as standardized treatment guidelines are lacking. Accurate diagnosis is imperative and requires thorough investigation to exclude a new occult primary malignancy or metastases from other tumors. Case Description: We report a detailed case of a 39-year-old female who developed synchronous CAM and extensive contralateral chest wall skin involvement, presenting as nodules and ulceration, 2 years after undergoing a right modified radical mastectomy for triple-negative breast cancer. Despite undergoing multiple lines of systemic therapy over several years, the disease progressed locally at these contralateral sites without evidence of other distant metastases. After comprehensive imaging and histopathological evaluation confirmed the metastatic origin from her primary breast cancer, the patient underwent aggressive local surgical resection. This included a left radical mastectomy with nipple-areola complex preservation, wide resection of the chest wall tumor, and immediate reconstruction using a pedicled latissimus dorsi flap. The patient tolerated the procedure well, achieved clear margins, and had a satisfactory postoperative recovery. Conclusions: CAM represents a complex clinical scenario that necessitates meticulous differential diagnosis and multimodal evaluation. The outcome of this case, alongside a review of the literature, suggests that in selected patients without concomitant distant metastases, CAM may behave as a locoregional progression rather than systemic dissemination. Therefore, a blanket classification as stage IV disease may lead to the undertreatment of potentially curable local recurrences. Current evidence supports considering an aggressive local therapeutic approach, including surgery and/or radiotherapy, combined with systemic therapy to enhance local control and improve prognosis. An individualized, comprehensive treatment strategy is strongly recommended to optimize survival outcomes in such rare cases.